Page 1123

Archive for the ‘Hypopituitarism’ Category

Familial hypopituitarism | Genetic and Rare Diseases …

If you have problems viewing PDF files, download the latest version of Adobe Reader

For language access assistance, contact the NCATS Public Information Officer

Genetic and Rare Diseases Information Center (GARD) – PO Box 8126, Gaithersburg, MD 20898-8126 – Toll-free: 1-888-205-2311

Read more from the original source:
Familial hypopituitarism | Genetic and Rare Diseases …

Severe hyponatremia due to hypopituitarism with adrenal …

Objective: Adrenal insufficiency due to hypopituitarism can lead to severe hyponatremia with potentially fatal consequences. Prompt diagnosis and adequate hormonal replacement therapy are essential to block an otherwise unfavorable course and to re-establish a healthy life. Unfortunately, this condition is often misdiagnosed. Design: Case report. Setting: Intensive Care Unit of a teaching hospital. Patient: A 76-yr-old man with refractory hypotension, acute myocardial infarction, and left ventricular dysfunction, secondary to severe chronic pan-hypopituitarism, associated with severe hyponatremia. Methods and main results: The patient underwent mechanical ventilation and continuous venous-venous hemodiafiltration, for severe respiratory and renal insufficiency. A hormonal replacement therapy with T4, hydrocortisone, and nandrolone was started and the patient was discharged to a rehabilitation facility after 31 days of hospitalization. Conclusions: Hypopituitarism with secondary adrenal insufficiency is often misdiagnosed at an early stage and a high degree of suspicion is necessary for early diagnosis. Determination of plasma cortisol level in patients with hyponatremia not explained by other causes should always be obtained.

Key-wordsHyponatremiapan-hypopituitarismadrenal insufficiencymyocardial infarctionhypothyroidism

Unable to display preview.Download preview PDF.

1.

Yatagai T, Kusaka I, Nakamura T, et al. Close association of severe hyponatremia with exaggerated release of arginine vasopressin in elderly subjects with secondary adrenal insufficiency. Eur J Endocrinol 2003, 148: 2216.

2.

Ishikawa SE, Saito T, Fukagawa A, et al. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab 2001, 86: 166571.

3.

Heneghan C, Goldrick P, Pham H. Management of acute symptomatic hyponatremia. BMJ 1994, 308: 203.

4.

Goldstein CS, Braunstein S, Goldfarb S. Idiopathic syndrome of inappropriate antidiuretic hormone secretion possibly related to advanced age. Ann Intern Med 1983, 99: 1858.

5.

Smith JC, Siddique H, Corrall RJM. Misinterpretation of serum cortisol in a patient with hyponatremia. BMJ 2004, 328: 2156.

6.

Surawicz B, Mangiardi ML. Electrocardiogram in endocrine and metabolic disorders. Cardiovasc Clin 1977, 8: 24366.

7.

Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002, 137: 90414.

8.

Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344: 5019.

9.

Hazouard E, Piquemal R, Dequin PF, Tayoro J, Valat C, Legras A. Severe non-infectious circulatory shock related to hypopituitarism. Intensive Care Med 1999, 25: 8658.

10.

Al Jarallah AS. Reversible cardiomyopathy caused by an uncommon form of congenital adrenal hyperplasia. Pediatr Cardiol 2004, 25: 6756.

11.

Francque SM, Schwagten VM, Ysebaert DK, Van Marck EA, Beaucourt LA. Bilateral adrenal haemorrhage and acute adrenal insufficiency in a blunt abdominal trauma: a case-report and literature review. Eur J Emerg Med 2004, 11: 1647.

12.

Yanagi N, Maruyama T, Arita M, Kaji Y, Niho Y. Alterations in electrical and mechanical activity in Langendorff-perfused guinea pig hearts exposed to decreased external sodium concentration with or without hypotonic insult. Pathophysiology 2001, 7: 25161.

Italian Society of Endocrinology (SIE)2007

More:
Severe hyponatremia due to hypopituitarism with adrenal …

Hypopituitarism | You and Your Hormones from the Society …

Alternative names for hypopituitarism

Hypopit; pituitary insufficiency; partial hypopituitarism; panhypopituitarism (pan referring to all pituitary hormones being affected); anterior hypopituitarism

Hypopituitarism is failure of the pituitary gland to produce one, some, or all of the hormones it normally produces. The pituitary gland has two parts, the anterior pituitary and the posterior pituitary, and hormone production can be affected in both parts.

Below are listed some of the causes of hypopituitarism:

The signs and symptoms of hypopituitarism depend on which of the pituitary gland hormones are involved, to what extent and for how long. It also depends on whether the hormone deficiencies began as a child or later in adult life. Symptoms can be slow at the start and vague.It is worth understanding the normal function and effects of these hormones in order to understand the signs and symptoms of hypopituitarism. (See the article on pituitary gland.) There may also be additional symptoms due to the underlying cause of the hypopituitarism, such as the effects of pressure from a tumour.

Symptoms can include:

Hypopituitarism is rare. At any given time, between 300 and 455 people in a million may have hypopituitarism. A number of endocrinologists believe that hypopituitarism is quite common after brain injuries. If this belief is confirmed, then hypopituitarism may be significantly more common than previously believed.

Most cases of hypopituitarism are not inherited.However, there are some very rare genetic abnormalities than can cause hypopituitarism.

Blood tests are required to check the level of the hormones, which are either produced by the pituitary gland itself, or by peripheral endocrine glands controlled by the pituitary gland. These blood tests may be one-off samples or the patient may require more detailed testing on a day-unit. These are called dynamic tests and they measure hormone levels before and after stimulation to see if the normal pituitary gland is working properly.They usually last between1 to 4 hours.

If it is suspected that there is a lack of anti-diuretic hormone, the doctor may organise a water deprivation test. The patient will be deprived of water for a period of eight hours under very close supervision with regular blood and urine tests.The test may be extended to a 24 hour period if needed, which means an overnight stay in hospital.

Other tests may also be organised to try and identify the underlying cause of the hypopituitarism. These could include blood tests, scans such as computerised tomography (CT) or magnetic resonance imaging (MRI) scans, and tests for vision.

Hypopituitarism is treated by replacing the deficient hormones. Treatment will be tailored to the individual depending on which hormones they are deficient in:

Since the treatment of hypopituitarism only involves replacing hormones that the body should be making but is unable to, there should be no side-effects if the appropriate amounts of hormones are replaced.Patients will be monitored to ensure they are receiving the correct amount of replacement hormones. Some side-effects can occur from hormone replacement if the amount replaced is higher than the individuals body requirements.If the patient has any concerns, they should discuss them with their doctor.

People with long-term hypopituitarism will need to take daily medication and will require regular checks with an endocrinologist at an outpatients clinic.

People with hypopituitarism may have an impaired quality of life.Hypopituitarism is associated with an increased risk of heart disease and strokes as a result of the physical changes that occur in body fat, cholesterol and circulation. Healthy living, a balanced diet and exercise to prevent becoming overweight are essential to reduce this risk.

People with hypopituitarism also have a higher risk of developing osteoporosis or brittle bones and, therefore, have a higher risk of developing fractures from minor injuries. A diet that is rich in calcium and vitamin d along with moderate amounts of weight-bearing exercise and training are helpful in decreasing this risk.

Appropriate pituitary hormone replacement therapy can reduce all these risks.

Last reviewed: Jan 2015

Visit link:
Hypopituitarism | You and Your Hormones from the Society …

The Pituitary Society | Glossary of Terms Related to …

ACTH

Adrenocorticotropic hormone. This hormone is produced by the pituitary gland and flows through the blood to the adrenal glands to tell them to produce more cortisol.

A benign tumor or growth. A pituitary adenoma is not cancerous.

Glands situated just above each of the kidneys and which produce various essential hormones including cortisol and aldosterone.

Surgical removal of the adrenal glands.

Anti-diuretic hormone or vasopressin. This hormone is produced by the pituitary and causes the kidneys to conserve body fluids.

An agonist is a molecule that triggers the same effects and actions as a naturally occurring molecule or hormone. It stimulates or activates cellular responses just like the natural hormone. For example, a dopamine agonist causes the same effect on cells as dopamine itself by binding to the same receptor on the surface of cells. This causes the cell to respond in the same way as it would in the presence of the real hormone.

The pituitary hormone that controls water balance.

Return to top

A drug of a type called dopamine agonists, which can be used to reduce prolactin production in people with prolactinomas. Its brand name is Parlodel and it is produced by Novartis.

Return to top

A drug of a type called dopamine agonists, which can be used to reduce prolactin production for people with prolactinomas. Its brand name is Dostinex and it is produced by Pfizer.

One of the hormones produced by the adrenal glands. It is particularly important in times of stress and illness.

A problem that occurred during fetal development (in the womb) that may grow at any time in life; not a cancer or brain tumor; often causes loss of pituitary function and may cause diabetes insipidus.

Corticotropin-releasing hormone normally made by the hypothalamus to stimulate ACTH production. In synthetic form, used to test for pituitary-dependent Cushing’s disease.

Cushing’s syndrome when caused by a tumour of the pituitary gland.

Caused by overproduction of cortisol for any reason.

Return to top

5-dehydroepiandrosterone is an steroid naturally produced by adrenal glands and synthesized in the brain. It is a prohormone, considered to be a precursor for the sex steroids.

A form of diabetes that results from water imbalance and is characterized by in frequent urination and excessive thirst.

A neurotransmitter mad in the brain which regulates prolactin secretion. The medicines used to treat prolactinomas are effective because they are designed to increase the action of dopamine.

Dopamine agonists such as bromocriptine (brand name Parlodel) and cabergoline (brand name Dostinex) inhibit GH release from the tumor. They work by stimulating natural receptorsof the hormone dopamine on the surface of the tumor. This sends messages into the tumor cells to stop producing GH.

Return to top

Production of ACTH from a site other than the pituitary gland.

Relating to hormone.

The body-wide system of hormone-producing glands, and the hormones they make, which control many aspects of life, including growth and reproduction.

A doctor who specializes in treating hormone illnesses.

Return to top

A medication that controls salt and water balance.

In every million people, three cases of acromegaly are diagnosed each year.

Follicle-stimulating hormone. This is one of the two pituitary hormones (with LH) that is released from the testes in men and the ovaries in women.

Return to top

A condition where a milky discharge is produced from the breasts in a woman who is not pregnant or lactating. Galactorrhea can also occur in men, but is rare.

Gigantism is a serious disorder where a person has grown very large and tall due to excess secretion of growth hormone from the pituitary gland during childhood. Heights of people suffering from this disorder can reach eight feet . For more information on this condition please visit: http://www.medterms.com/script/main/art.asp?articlekey=4914

As the name suggests, growth hormone (GH) stimulates physical growth in children. It is a hormone that is produced by the pituitary gland and has widespread effects on the body. After you have stopped growing at 17 or 18, the skeleton changes and is no longer able to increase in height. However, growth hormone still plays important roles in adulthood, such as maintaining muscle tone and regulating metabolism, energy levels and psychological wellbeing.

Return to top

A chemical substance produced by the endocrine glands of the body, which works by sending messages through the bloodstream.

Hormone therapy is the term used for any pharmaceutical/drug therapy given to an individual to provide particular hormones that are missing or present at an abnormally low level. If the pituitary gland is not functioning, specific hormonal therapy will be prescribed to replace those hormones that the gland would normally produce.

The drug name of cortisol when it is made into a tablet or injection.

A medical condition in which a patient has elevated blood levels of prolactin, most often due to a pituitary tumor (a prolactinoma). Normal prolactin levels are less than 25 ng/ml in women and less than 17 ng/ml in men. In addition to a pituitary tumor, some medications, hypothyroidism, and kidney disease can lead to elevated serum levels of prolactin.

Hypopituitarism is a disorder in which the pituitary gland does not produce the normal amounts of some or all of its hormones. Hypopituitarism can affect several systems and cause growth failure in children, low thyroid hormone production (necessary for metabolism), low cortisol (steroid) production, and loss of reproductive function (loss of menstrual cycles in women, low testosterone in men and problems with fertility in both men and women). This is an uncommon condition and all missing hormones can be replaced.

Return to top

IGF-1 is a very important hormone involved in growth and development, and it is made by many tissues in the body. IGF stands for insulin-like growth factor but you will probably hear the hormone referred to as I-G-F-one.

Insulin is a hormone secreted by a group of islet cells within the pancreas, which is an organ located near the stomach. Most cells in the body have insulin receptors that bind to circulating insulin, which triggers the cell to absorb glucose (sugar). Without insulin, cells are starved because they cannot access the calories contained in the glucose.

Return to top

Luteinizing hormone. This hormone is produced by the pituitary and sends messages to the reproductive organs (called gonads) the ovaries in women and testes in men. In children, LH contributes to sexual development. In women, it works together with FSH to control ovulation and is thus essential for a normal menstrual cycle and for fertility. In men FSH stimulates the testes to produce sperm.

Return to top

A prolactinoma that is 10 mm or larger.

A prolactinoma that is smaller than 10 mm (or about 1/2 inch).

Magnetic resonance imaging – a type of scan that produces a clear image and which is used to determine the size and location of the tumour.

Return to top

Pituitary hormone that causes contraction of the uterus during labor.

Return to top

Pegvisomant is a growth hormone antagonist. It does not lower the level of GH released from the tumor but it stops the hormone from acting on its targets in various parts of the body. This then prevents the effects of too much GH, such as overproduction of IGF-I. To do this pegvisomant binds to the natural receptors for growth hormone and gets in the way of the hormone being able to bind and send messages into cells. Imagine forcing the wrong key into a lock; the correct key cannot then fit in, and the lock cannot be opened.

A drug that is used to reduce prolactin production in people with prolactinomas. Its brand name is Permax and it is produced by Eli Lilly.

The pituitary gland is an important gland and it is often referred to as the ‘master gland’, because it controls several of the other hormone-producing glands. It is usually about the size of a pea and is situated in a bony hollow beneath the base of the brain and just behind the bridge of your nose. The gland consists of two parts (often called lobes) each of which has different functions. The pituitary gland is also sometimes called the hypophysis.

Prolactin. This hormone is produced by the pituitary and is usually best known as the milk hormone, because its main purpose is to stimulate the breasts to produce milk after childbirth. However, men and women produce prolactin all the time. Its purpose in men is unclear.

A hormone produced by the pituitary gland that stimulates the production of breast milk during pregnancy and the postpartum period.

An abnormal growth, or tumor, on the pituitary gland. The tumor is almost always noncancerous (benign) and causes the pituitary to produce too much prolactin which leads to hyperprolactinemia.

Return to top

A dopamine agonist approved for use in Europe, Canada, and Australia. The drug is not approved by the FDA for treatment of hyperprolactinemia in the US.

Return to top

Finely targeted radiation therapy using MRI to pinpoint the tumour.

Radiation treatment, usually used after surgery, which prevents regrowth of the tumour. Radiotherapy has a long-acting effect and may cause reduction of some of the other pituitary hormones over time, thus requiring them to be replaced.

A receptor is a specialized protein on the surface or interior of a cell that interacts only with very specific molecules in the surrounding environment. Receptors enable molecules or drugs outside cells to communicate a signal to the interior, causing a response within that cell.

Return to top

These mimic a natural hormone, called somatostatin, and latch onto the hormones natural receptors on the surface of the tumor. When this lock and key connection is made specific signals are sent into the tumor cells to make them stop producing GH.

Stimulation testing is conducted when your health care provider suspects you are not producing the appropriate amount of a hormone. The test varies depending on which hormone is being evaluated, but the test typically involves a pretest phase during which you may be required to fast or eat a very specific diet, and then a blood sample is collected.

Return to top

The thyroid is a gland that lies over the windpipe and just below the larynx. It produces hormones which are essential to numerous body processes.

Thyroid-stimulating hormone. A hormone produced by the pituitary, which sends a message to the thyroid gland to increase or decrease its production of the hormone, thyroxine.

A method of operating on the pituitary gland by making an incision in front of the upper teeth and behind the upper lip, or alternatively inside the nose. This allows the surgeon access to the pituitary via the sphenoid sinus and minimizes trauma to the patient.

Return to top

2003 Pituitary Society. All Rights Reserved. E&OE.

Originally posted here:
The Pituitary Society | Glossary of Terms Related to …

What Is Hypopituitarism (Dwarfism)? – Verywell

Hypopituitarism (dwarfism) is a rare disease that results from the low production of hormones in the pituitary gland. The pituitary gland is located deep within your brain and is an important aspect of the endocrine system.

In children, human growth hormone deficiencies can lead to impaired growth, also known as dwarfism. Early diagnosis and medical intervention can sometimes correct this deficiency, allowing the affected individual to reach a normal or near-normal height.

In addition to stunted growth, hypopituitarism can also cause deficiencies in thyroid or adrenal hormones.

The most common cause of hypopituitarism is a tumor located in or around the pituitary gland. Surgery or radiation therapy near the pituitary gland can also stimulate dwarfism. In some rare cases, illnesses like tuberculosis can cause inflammation that causes hypopituitarism as well.

Besides slowed growth, there are many other symptoms of hypopituitarism:

Diagnosing hypopituitarism can be difficult as it often goes unnoticed early on. During the first two years of life, a child with growth hormone deficiency may grow at a normal rate and may seem perfectly healthy.

As the child becomes older, however, parents may notice that their child does not seem to be growing properly. The child may be smaller when compared to other kids his age and may look younger than them or have different proportions.

A child who grows less than 2 inches per year, or who is only as tall as children two or more years younger, should be evaluated by a physician for growth hormone deficiency after other possible causes, such as hypothyroidism, have been ruled out.

Your child’s doctor will look at the patient history, perform a physical exam and may recommend an X-ray to look for the presence of a tumor. He may also perform blood tests to check pituitary, thyroid and adrenal glands.

Testing for growth hormone deficiency is done by stimulating the body to produce the hormone and then measuring how much hormone is actually released.

In most cases, people with hypopituitarism will undergo hormonal therapy throughout their entire lifetimes. Depending on the individual’s deficiency, different hormones may be administered.

In order for a more normal height to be achieved, children will need to have human growth hormone replacement therapy. Growth hormone deficiency is treated by injections of a growth hormone preparation such as Humatrope (somatropin). A child may receive daily or weekly injections. The child’s growth rate increases soon after the injections are started. The treatment continues over several years until the child’s maximum growth potential is achieved. Most children will reach an “acceptable” adult height.

The average adult height for someone with untreated severe growth hormone deficiency is 4 feet, 8 inches in men and 4 feet, 3 inches in women, while those who undergo early treatments will reach more average heights in the range of 5 feet and up.

Sources:

Human Growth Foundation. “Disorders of Growth.” 2009.

Levy, Richard. “Growth Hormone Deficiency in Children.” The Magic Foundation.2009.

Pituitary Network Association. “Hypopituitarism.” 2014.

Go here to see the original:
What Is Hypopituitarism (Dwarfism)? – Verywell

Hormone Replacement Therapy Market: Industry Players to Show High Growth Rate by 2024 – Monotone Critic

Global Hormone Replacement Therapy Market: Overview

The medical treatment where the patients receive hormones to substitute the naturally occurring hormones with the other hormones or to add naturally occurring hormones that are absent is known as hormone replacement therapy. In the females that are at the stage of menopause, hormone replacement therapy is used to restore female hormone levels, so that the body functions normally.

Request Free Sample Report @ https://www.zionmarketresearch.com/sample/hormone-replacement-therapy-market

Global Hormone Replacement Therapy Market: Segmentation

The global hormone replacement therapy is fragmented into therapy type, distribution channel, and application. On the basis of a therapy type, the global market is segregated into estrogen replacement therapy, thyroid hormone replacement, and growth hormone replacement. The thyroid hormone replacement segment is further sub-segmented into tablets, injections, and capsules. The growth hormone replacement segment is sub-categorized into somatostatin analogs and dopamine agonist. On the basis of the distribution channel, the market is categorized into e-commerce, retail pharmacies and drugstores, hospital pharmacies, compounding pharmacies, and others. On the basis of application, the market is divided into hypothyroidism, menopause, cancer, hypopituitarism, and others.

Global Hormone Replacement Therapy Market: Growth Factors

The key factors that are driving the hormone replacement therapy market are enlarged demand for the regenerative medicines which include reproductive-cycle boosting and anti-aging. The market is being positively impacted due to the increasing demand from other therapeutic areas which include thyroid hormone therapy and growth hormone therapy as the hormone replacement therapy is comparatively safe and efficient method and is cost effective. The other benefits that are associated with the hormone replacement therapy include minimum risk incidence of cardiovascular disease, osteoporosis, and vasomotor symptoms are also reduced thus expecting to fuel the growth of hormone replacement therapy market. The limitations of the hormone replacement therapy market include the side effects that are involved in this therapy such as fluid retention, indigestion, headache, and depression thus hindering the popularity of the therapeutic area.

Request Report TOC (Table of Contents) @ https://www.zionmarketresearch.com/toc/hormone-replacement-therapy-market

Global Hormone Replacement Therapy Market: Regional Analysis

Regional diversification of the hormone replacement therapy market is given as follows Asia Pacific, Latin America, the Middle East & Africa, Western Europe, Eastern Europe, and North America. The region that is dominating the hormone replacement therapy market is North America, which is due to the fact that the U.S has the largest market owing to the popularity of the therapy among the patients that are aged 35 years and above. The factors that are contributing to the market growth in this region are increasing disposable income, early aging, and the availability of compounded drugs. In the coming years, the hormone replacement therapy market will grow speedily in Asia Pacific region owing to the increasing awareness among the people. The emerging nations such as India, Japan, and China will contribute largely to the market growth.

Browse detail report @ https://www.zionmarketresearch.com/report/hormone-replacement-therapy-market

Global Hormone Replacement Therapy Market: Competitive Players

The key market players that are involved in the hormone replacement therapy market include Pfizer, BioSante Pharmaceuticals and Amgen, Noven Pharmaceuticals, Bayer AG, Merck & co., and QuatRx Pharmaceuticals.

Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/hormone-replacement-therapy-market

About Us: Zion Market Research is an obligated company. We create futuristically, cutting edge, informative reports ranging from industry reports, a company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with Vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from Cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

4283, Express Lane,

Suite 634-143,

Sarasota, Florida 34249, United States

Tel: +49-322 210 92714

USA/Canada Toll-Free No.1-855-465-4651

Email: sales@zionmarketresearch.com

Website: http://www.zionmarketresearch.com

Visit Our Blog: https://zionmarketresearch.wordpress.com

Follow this link:
Hormone Replacement Therapy Market: Industry Players to Show High Growth Rate by 2024 – Monotone Critic

Hormone Replacement Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016 … – Digital Journal

Zion Market Research, the market research group announced the analysis report titled ‘Hormone Replacement Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20162024’

This press release was orginally distributed by SBWire

Sarasota, FL — (SBWIRE) — 07/27/2017 — Global Hormone Replacement Therapy Market: Overview

The medical treatment where the patients receive hormones to substitute the naturally occurring hormones with the other hormones or to add naturally occurring hormones that are absent is known as hormone replacement therapy. In the females that are at the stage of menopause, hormone replacement therapy is used to restore female hormone levels, so that the body functions normally.

Request Free Sample Report @ https://www.zionmarketresearch.com/sample/hormone-replacement-therapy-market

Global Hormone Replacement Therapy Market: Segmentation

The global hormone replacement therapy is fragmented into therapy type, distribution channel, and application. On the basis of a therapy type, the global market is segregated into estrogen replacement therapy, thyroid hormone replacement, and growth hormone replacement. The thyroid hormone replacement segment is further sub-segmented into tablets, injections, and capsules. The growth hormone replacement segment is sub-categorized into somatostatin analogs and dopamine agonist. On the basis of the distribution channel, the market is categorized into e-commerce, retail pharmacies and drugstores, hospital pharmacies, compounding pharmacies, and others. On the basis of application, the market is divided into hypothyroidism, menopause, cancer, hypopituitarism, and others.

Global Hormone Replacement Therapy Market: Growth Factors

The key factors that are driving the hormone replacement therapy market are enlarged demand for the regenerative medicines which include reproductive-cycle boosting and anti-aging. The market is being positively impacted due to the increasing demand from other therapeutic areas which include thyroid hormone therapy and growth hormone therapy as the hormone replacement therapy is comparatively safe and efficient method and is cost effective. The other benefits that are associated with the hormone replacement therapy include minimum risk incidence of cardiovascular disease, osteoporosis, and vasomotor symptoms are also reduced thus expecting to fuel the growth of hormone replacement therapy market. The limitations of the hormone replacement therapy market include the side effects that are involved in this therapy such as fluid retention, indigestion, headache, and depression thus hindering the popularity of the therapeutic area.

Request Report TOC (Table of Contents) @ https://www.zionmarketresearch.com/toc/hormone-replacement-therapy-market

Global Hormone Replacement Therapy Market: Regional Analysis

Regional diversification of the hormone replacement therapy market is given as follows Asia Pacific, Latin America, the Middle East & Africa, Western Europe, Eastern Europe, and North America. The region that is dominating the hormone replacement therapy market is North America, which is due to the fact that the U.S has the largest market owing to the popularity of the therapy among the patients that are aged 35 years and above. The factors that are contributing to the market growth in this region are increasing disposable income, early aging, and the availability of compounded drugs. In the coming years, the hormone replacement therapy market will grow speedily in Asia Pacific region owing to the increasing awareness among the people. The emerging nations such as India, Japan, and China will contribute largely to the market growth.

Browse detail report @ https://www.zionmarketresearch.com/report/hormone-replacement-therapy-market

Global Hormone Replacement Therapy Market: Competitive Players

The key market players that are involved in the hormone replacement therapy market include Pfizer, BioSante Pharmaceuticals and Amgen, Noven Pharmaceuticals, Bayer AG, Merck & co., and QuatRx Pharmaceuticals.

Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/hormone-replacement-therapy-market

About Zion Market ResearchZion Market Research is an obligated company. We create futuristically, cutting edge, informative reports ranging from industry reports, a company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with Vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from Cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

For more information on this press release visit: http://www.sbwire.com/press-releases/hormone-replacement-therapy/release-840079.htm

View post:
Hormone Replacement Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016 … – Digital Journal

Male Hypogonadism Market Deep Research Study with Forecast by 2025 – Digital Journal

The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities.

This press release was orginally distributed by SBWire

San Francisco, CA — (SBWIRE) — 07/11/2017 — Global Male Hypogonadism Market: Snapshot

Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in severity from person to person. It is often the cause of partial or complete infertility. There are multiple forms of male hypogonadism and even more ways to classify them. Most endocrinologists commonly classify male hypogonadism on the basis of the level of defectiveness of the male reproductive system.

In many cases, doctors also measure the level of gonadotropins to classify a patient between primary and secondary male hypogonadism. Primary male hypogonadism refers to the cause of the condition being due to defective gonads. There are different types of primary male hypogonadism, including Turner syndrome and Klinefelter syndrome. Secondary male hypogonadism is caused by defects in pituitary or hypothalamic glands. They include Kallmann syndrome and hypopituitarism.

Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1127

Global Male Hypogonadism Market: Overview

Male Hypogonadism refers to a clinical condition, wherein the testes fail to produce enough testosterone leading to delayed puberty or incomplete development. The condition is related to impaired development of muscle mass, development of breast tissues, impaired body hair growth, and lack of deepening of the voice.

The male Hypogonadism market can be segmented by therapy, type, drug delivery, and geography.

The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1127

Global Male Hypogonadism Market: Trends and Opportunities

The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the market’s growth.

However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lip’ral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the market’s growth.

Global Male Hypogonadism Market: Regional Overview

The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe.

Read Comprehensive Overview of Report@ https://www.tmrresearch.com/male-hypogonadism-market

Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism.

Major Companies Mentioned in Report

Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring.

Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner.

About TMR Research TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

For more information on this press release visit: http://www.sbwire.com/press-releases/male-hypogonadism-market/release-831100.htm

See the article here:
Male Hypogonadism Market Deep Research Study with Forecast by 2025 – Digital Journal

Treatment of hypopituitarism – uptodate.com

INTRODUCTION

Treatment of patients with hypopituitarism is the sum of the treatments of each of the individual pituitary hormonal deficiencies detected when a patient with a pituitary or hypothalamic disease is tested. The treatments of corticotropin (ACTH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) deficiencies are in many ways the same as the treatments of primary deficiencies of the respective target glands, but in other ways they differ. Both the similarities and differences will be highlighted below. Treatment of growth hormone (GH) deficiency is unique to hypopituitarism.

The specifics of therapy for hypopituitarism will be reviewed here. The causes, clinical manifestations, and diagnosis of hypopituitarism, as well as GH deficiency in adults and the management of individual hormone deficiencies, are reviewed in more detail elsewhere. (See “Causes of hypopituitarism” and “Clinical manifestations of hypopituitarism” and “Diagnostic testing for hypopituitarism” and “Growth hormone deficiency in adults”.)

IMPORTANCE OF TREATMENT

One reason to optimize treatment is that in a retrospective study of 344 patients who had hypopituitarism after pituitary surgery, the long-term mortality was about double that of the general population [1]. Most of the excess mortality was due to cerebrovascular disease. The relationship between the hypopituitarism and the excess mortality remains unknown, and we do not know if even optimal treatment will improve mortality.

ACTH DEFICIENCY

The primary consequence of lack of corticotropin (ACTH) is cortisol deficiency. As a result, treatment consists of the administration of hydrocortisone or other glucocorticoid in an amount and timing to mimic the normal pattern of cortisol secretion. Because there is no test to assess the adequacy of the replacement, the optimal replacement glucocorticoid and the optimal doses are not known. Most authorities recommend replacement with hydrocortisone because that is the hormone the adrenal glands make normally, but others prefer prednisone or dexamethasone for their longer durations of action.

Preparation and doseMost authorities recommend hydrocortisone doses of 15 to 25 mg/day [2,3] because those doses are similar to daily production rates [4]. Patients who are more severely deficient or weigh more tend to need doses at the upper end of this range and vice versa. Some patients, however, need even larger doses to avoid severely symptomatic adrenal insufficiency, and others can get by on smaller amounts.

Literature review current through: Apr 2017. | This topic last updated: Nov 03, 2015.

Here is the original post:
Treatment of hypopituitarism – uptodate.com

Clinton child battles rare genetic disorder – Utica Observer Dispatch

Amy Neff Roth

Dominic Tebo has gotten a lot of love and a lot of medical care in his young life.

The Clinton 2-year old was born with an array of medical problems and has undergone many treatments. His parents put the other parts of their lives on hold for six months so they could stay in Syracuse while he remained in the neonatal intensive care unit.

Now Dominic needs one thing his parents cant afford to give him an accessible home.

My child has love. He has toys. He has everything that a 2-year-old needs, a normal two-year old. But unfortunately, I cannot give him the room to keep progressing, said Dominics mother, Monica Moffo.

So the Lake Delta Kiwanis are stepping in, hosting a fundraiser Sunday in Lee Center to raise money for the family. It will take place from noon to 5 p.m. at the Lee Center Fire Hall at 5510 School St. It will feature a chicken barbecue, live music and 50/50 and gift basket raffles. The cost is $10 per person.

Moffo and her fianc, Eric Tebo, Dominics father, lived in Lee Center before they temporarily stopped working to be with Dominic. Now they live in Clinton with Moffos mother.

Dominic has a rare gene mutation known as MAG-2. His doctor told the family that hes one of only five people in the world and the only one in the United States known to have the condition, Moffo said. Its rarity is apparent in the lack of information available through a Google search.

He has all his chromosomes and out of one of his chromosomes theres thousands of letters in a chromosome out of all of his chromosomes, hes missing one letter, Moffo explained.

Moffo said theyve been told that all the people with the mutation have respiratory problems like Dominic. But Dominic was born with a laundry list of medical conditions, many of which the others do not have, Moffo said.

Dominic was born with hypopituitarism (malfunctioning of the pituitary gland), tracheomalachia (in which the cartilage is so soft that the trachea partially collapses), clench hands, club feet, bell-shaped lungs and an enlarged tongue. He has a tracheotomy to help his breathing and had surgery on his tongue a year and a half ago. He used to be on a feeding tube, but hes able to eat on his own now.

Hes had multiple surgeries, some life threatening, and has been in and out of the hospital. Hes about to scooch around the house now and is learning to use a walker, his mother said. He also has a weakened immune system so his family tried to keep him somewhat isolated.

Its not clear if all his problems are linked to his genetic defect or if he has another medical condition as well.

They literally consider him an open book mystery, Moffo said.

Despite the challenges, Dominic has come a long way, she said.

Hes a very happy boy, she said, and always a smile, no matter what.

Follow @OD_Roth on Twitter or call her at 315-691-2961

Read this article:
Clinton child battles rare genetic disorder – Utica Observer Dispatch

FDA Grants BAVENCIO (avelumab) Approval for a Common Type of Advanced Bladder Cancer – PR Newswire (press release)

ROCKLAND, Mass. and NEW YORK, May 9, 2017 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO (avelumab) Injection for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. BAVENCIO was previously granted accelerated approval from the FDA for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). These indications are approved under accelerated approval based on tumor response and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.1

“This approval for BAVENCIO in patients with locally advanced or metastatic urothelial carcinoma exemplifies our unwavering commitment to finding new treatments for the most challenging cancers,” said Luciano Rossetti, M.D., Executive Vice President, Global Head of Research & Development at the biopharma business of Merck KGaA, Darmstadt, Germany. “Coming just a few weeks after the approval for metastatic Merkel cell carcinoma, we continue to demonstrate our ability to accelerate access to innovative medicines for patients in need.”

“This approval builds on the ongoing clinical development program for BAVENCIO in urothelial carcinoma and reinforces our commitment to providing new medicines to patients with difficult-to-treat cancers,” said Liz Barrett, Global President, Pfizer Oncology. “By drawing on the strength of the alliance, as well as Pfizer’s deep experience in genitourinary cancers, we believe BAVENCIO will be an important treatment option, and we hope it will help to improve outcomes for these patients.”

Bladder cancer makes up approximately 90% of urothelial carcinomas and is the sixth most common cancer in the US.2,3 When the disease has metastasized, the five-year survival rate is approximately 5%.4 Despite advances in the treatment of locally advanced or metastatic urothelial carcinoma, the prognosis for patients remains poor and more treatment options are needed.2

“Once urothelial carcinoma progresses after treatment with chemotherapy, the five-year survival rate is alarmingly low,” said Dr. Andrea Apolo, National Cancer Institute, Bethesda, MD, US. “Until recently, there had been limited innovation in urothelial carcinoma, and this approval gives us another treatment to help battle this aggressive disease.”

The efficacy and safety of BAVENCIO was demonstrated in the urothelial carcinoma cohorts (N=242) of the JAVELIN Solid Tumor trial, a Phase I, open-label, single-arm, multicenter study of BAVENCIO in the treatment of various solid tumors. The urothelial carcinoma cohorts enrolled patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy or who had disease progression within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant chemotherapy regimen. These data will be presented at an upcoming medical congress.

The warnings and precautions for BAVENCIO include immune-mediated adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction and other adverse reactions), infusion-related reactions and embryo-fetal toxicity. The most common adverse reactions (reported in at least 20% of patients) in patients with locally advanced or metastatic urothelial carcinoma were fatigue (41%), infusion-related reaction (30%), musculoskeletal pain (25%), nausea (24%), decreased appetite/hypophagia (21%) and urinary tract infection (21%).1 For more information, please see Important Safety Information for BAVENCIO below.

BAVENCIO is designed to potentially engage both the adaptive and innate immune systems. By binding to PD-L1, BAVENCIO is thought to prevent tumor cells from using PD-L1 for protection against white blood cells, such as T cells, exposing them to anti-tumor responses.1 BAVENCIO has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.1

The alliance is committed to providing industry-leading patient access and reimbursement support through its CoverOne program. This program provides a spectrum of patient access and reimbursement support services intended to help patients receive appropriate access to BAVENCIO in the United States. CoverOne may be reached by phone at 844-8COVER1 (844-826-8371) or online at http://www.CoverOne.com.

About Urothelial Carcinoma Cohorts in JAVELIN Solid Tumor Trial The efficacy and safety of BAVENCIO was demonstrated in the urothelial carcinoma cohorts of the JAVELIN Solid Tumor trial, a Phase I, open-label, single-arm, multicenter study that included 242 patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum- containing chemotherapy or who had disease progression within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant chemotherapy regimen who were treated with BAVENCIO.

Patients with active or a history of central nervous system metastasis; other malignancies within the last five years; an organ transplant; conditions requiring therapeutic immune suppression; or active infection with HIV, hepatitis B or C were excluded. Patients with autoimmune disease, other than type 1 diabetes, vitiligo, psoriasis, or thyroid disease that did not require immunosuppressive treatment, were excluded. Patients were included regardless of their PD-L1 status. Patients received BAVENCIO at a dose of 10 mg/kg intravenously over 60 minutes every two weeks until disease progression or unacceptable toxicity. Tumor response assessments were performed every six weeks, as assessed by an Independent Endpoint Review Committee (IERC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Efficacy outcome measures included confirmed overall response rate, (ORR) and duration of response (DOR). Efficacy measures were evaluated in patients who were followed for a minimum of both 13 weeks and 6 months at the time of data cut-off.

Out of the total 226 patients evaluable for efficacy, 44% had non-bladder urothelial carcinoma, including 23% of patients with upper tract disease; 83% of patients had visceral metastases; 34% of patients had liver metastases. Nine patients (4%) had disease progression following prior platinum-containing neoadjuvant or adjuvant therapy only. Forty-seven percent of patients only received prior cisplatin-based regimens, 32% received only prior carboplatin-based regimens, and 20% received both cisplatin and carboplatin-based regimens.

The international clinical development program for avelumab, known as JAVELIN, involves more than 30 clinical programs, including nine Phase III trials, and more than 5,200 patients across more than 15 tumor types.

In December 2015, Merck KGaA, Darmstadt, Germany and Pfizer announced the initiation of a Phase III multicenter, multinational, randomized, open-label, parallel-arm study (JAVELIN Bladder 100) of BAVENCIO plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma whose disease did not progress after completion of first-line platinum-containing chemotherapy. This trial is currently enrolling patients.

For more information about JAVELIN trials, please visit http://www.clinicaltrials.gov.

For full prescribing information and medication guide for BAVENCIO, please see http://www.BAVENCIO.com.

IMPORTANT SAFETY INFORMATION and INDICATIONS

BAVENCIO can cause immune-mediated pneumonitis, including fatal cases. Monitor patients for signs and symptoms of pneumonitis and evaluate suspected cases with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent moderate (Grade 2) pneumonitis. Pneumonitis occurred in 1.2% (21/1738) of patients, including one (0.1%) patient with Grade 5, one (0.1%) with Grade 4, and five (0.3%) with Grade 3.

BAVENCIO can cause immune-mediated hepatitis, including fatal cases. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater hepatitis. Withhold BAVENCIO for moderate (Grade 2) immune-mediated hepatitis until resolution and permanently discontinue for severe (Grade 3) or life-threatening (Grade 4) immune-mediated hepatitis. Immune-mediated hepatitis was reported in 0.9% (16/1738) of patients, including two (0.1%) patients with Grade 5 and 11 (0.6%) with Grade 3.

BAVENCIO can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold BAVENCIO until resolution for moderate or severe (Grade 2 or 3) colitis and permanently discontinue for life-threatening (Grade 4) or recurrent (Grade 3) colitis upon re-initiation of BAVENCIO. Immune-mediated colitis occurred in 1.5% (26/1738) of patients, including seven (0.4%) with Grade 3.

BAVENCIO can cause immune-mediated endocrinopathies, including adrenal insufficiency, thyroid disorders, and type 1 diabetes mellitus.

Monitor patients for signs and symptoms of adrenal insufficiency during and after treatment, and administer corticosteroids as appropriate. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. Adrenal insufficiency was reported in 0.5% (8/1738) of patients, including one (0.1%) with Grade 3.

Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation. Manage hypothyroidism with hormone replacement therapy and hyperthyroidism with medical management. Withhold BAVENCIO for severe (Grade 3) or life- threatening (Grade 4) thyroid disorders. Thyroid disorders including hypothyroidism, hyperthyroidism, and thyroiditis were reported in 6% (98/1738) of patients, including three (0.2%) with Grade 3.

Type 1 diabetes mellitus including diabetic ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Withhold BAVENCIO and administer anti-hyperglycemics or insulin in patients with severe or life-threatening (Grade 3) hyperglycemia, and resume treatment when metabolic control is achieved. Type 1 diabetes mellitus without an alternative etiology occurred in 0.1% (2/1738) of patients, including two cases of Grade 3 hyperglycemia.

BAVENCIO can cause immune-mediated nephritis and renal dysfunction. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater nephritis. Withhold BAVENCIO for moderate (Grade 2) or severe (Grade 3) nephritis until resolution to Grade 1 or lower. Permanently discontinue BAVENCIO for life-threatening (Grade 4) nephritis. Immune-mediated nephritis occurred in 0.1% (1/1738) of patients.

BAVENCIO can result in other severe and fatal immune-mediated adverse reactions involving any organ system during treatment or after treatment discontinuation. For suspected immune-mediated adverse reactions, evaluate to confirm or rule out an immune-mediated adverse reaction and to exclude other causes. Depending on the severity of the adverse reaction, withhold or permanently discontinue BAVENCIO, administer high-dose corticosteroids, and initiate hormone replacement therapy if appropriate. Resume BAVENCIO when the immune-mediated adverse reaction remains at Grade 1 or lower following a corticosteroid taper. Permanently discontinue BAVENCIO for any severe (Grade 3) immune-mediated adverse reaction that recurs and for any life-threatening (Grade 4) immune-mediated adverse reaction. The following clinically significant immune-mediated adverse reactions occurred in less than 1% of 1738 patients treated with BAVENCIO: myocarditis with fatal cases, myositis, psoriasis, arthritis, exfoliative dermatitis, erythema multiforme, pemphigoid, hypopituitarism, uveitis, Guillain-Barr syndrome, and systemic inflammatory response.

BAVENCIO can cause severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Patients should be premedicated with an antihistamine and acetaminophen prior to the first 4 infusions and for subsequent doses based upon clinical judgment and presence/severity of prior infusion reactions. Monitor patients for signs and symptoms of infusion-related reactions, including pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. Permanently discontinue BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Infusion-related reactions occurred in 25% (439/1738) of patients, including three (0.2%) patients with Grade 4 and nine (0.5%) with Grade 3.

BAVENCIO can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus including the risk of fetal death. Advise females of childbearing potential to use effective contraception during treatment with BAVENCIO and for at least 1 month after the last dose of BAVENCIO. It is not known whether BAVENCIO is excreted in human milk. Advise a lactating woman not to breastfeed during treatment and for at least 1 month after the last dose of BAVENCIO due to the potential for serious adverse reactions in breastfed infants.

The most common adverse reactions (all grades, 20%) in patients with metastatic Merkel cell carcinoma (MCC) were fatigue (50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%), infusion-related reaction (22%), rash (22%), decreased appetite (20%), and peripheral edema (20%).

Selected treatment-emergent laboratory abnormalities (all grades, 20%) in patients with metastatic MCC were lymphopenia (49%), anemia (35%), increased aspartate aminotransferase (34%), thrombocytopenia (27%), and increased alanine aminotransferase (20%).

The most common adverse reactions (all grades, 20%) in patients with locally advanced or metastatic urothelial cancer (UC) were fatigue (41%), infusion-related reaction (30%), musculoskeletal pain (25%), nausea (24%), decreased appetite/hypophagia (21%) and urinary tract infection (21%).

Selected laboratory abnormalities (grades 3-4, 3%) in patients with locally advanced or metastatic UC were hyponatremia (16%), gamma-glutamyltransferase increased (12%), lymphopenia (11%), hyperglycemia (9%), increased alkaline phosphatase (7%), anemia (6%), increased lipase (6%), hyperkalemia (3%), and increased aspartate aminotransferase (3%).

INDICATIONS

BAVENCIO is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).

BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

These indications are approved under accelerated approval based on tumor response and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Please see full Prescribing Information and Medication Guide.

Avelumab has not yet been approved for any indication in any market outside of the US. As announced on October 31, 2016, the European Medicines Agency (EMA) has validated for review Merck KGaA, Darmstadt, Germany’s Marketing Authorization Application for avelumab, for the proposed indication of metastatic Merkel cell carcinoma.

About BAVENCIO (avelumab) BAVENCIO is a human programmed death ligand-1 (PD-L1) blocking antibody indicated in the US for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, as well as for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.1 These indications are approved under accelerated approval based on tumor response and duration of response. Continued approval for these indications is contingent upon verification and description of clinical benefit in confirmatory trials.

BAVENCIO is not approved for any indication in any market outside the US.

Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US Immuno-oncology is a top priority for Merck KGaA, Darmstadt, Germany and Pfizer Inc. The global strategic alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US, enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck KGaA, Darmstadt, Germany. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab as a monotherapy, as well as in combination regimens, and is striving to find new ways to treat cancer.

About EMD Serono, Inc. EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany a leading science and technology company in the US and Canada focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has 1,200 employees around the country with commercial, clinical and research operations based in the company’s home state of Massachusetts. http://www.emdserono.com

About Merck KGaA, Darmstadt, Germany All Merck KGaA, Darmstadt, Germany Press Releases are distributed by e-mail at the same time they become available on the Merck KGaA, Darmstadt, Germany Website. Please go to http://www.emdgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of 15.0 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the “Merck” name and brand except in the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Pfizer Inc.: Working together for a healthier world At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.pfizer.com. In addition, to learn more, please visit us on http://www.pfizer.com and follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice The information contained in this release is as of May 9, 2017. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about BAVENCIO (avelumab), the alliance between Merck KGaA, Darmstadt, Germany and Pfizer involving anti-PD-L1 and anti-PD-1 therapies, and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of BAVENCIO; the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any other jurisdictions for the Indication or in any jurisdictions for any other potential indications for BAVENCIO, combination therapies or other product candidates; whether and when any such applications (including the pending application for BAVENCIO for metastatic Merkel cell carcinoma in the EU) may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of BAVENCIO, combination therapies or other product candidates; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov and http://www.pfizer.com.

References

Your Contacts

EMD Serono Inc.

Media

Melissa Lauer

+1 781 738 5673

Investor Relations

+49 6151 72 3321

Pfizer Inc., New York, USA

Media

Sally Beatty

+1 212 733 6566

Investor Relations

Ryan Crowe

+1 212 733 8160

SOURCE EMD Serono; Pfizer

Excerpt from:
FDA Grants BAVENCIO (avelumab) Approval for a Common Type of Advanced Bladder Cancer – PR Newswire (press release)

Radiation Tx for Persistent Acromegaly Safe, Effective – MedPage Today

Action Points

AUSTIN — Following pituitary surgery, radiation for persistent or recurrent acromegaly was shown to be an effective and safe treatment, researchers reported here.

In a retrospective analysis, patients with acromegaly who had undergone pituitary surgery and then received radiation therapy had twice the remission rate seen in those who did not receive radiation (RR 2.1, 95% CI 1.1-4.3, P=0.036), according to Diane Donegan, MD BCh BAO, senior clinical fellow of the Mayo Clinic, and colleagues.

The study reported that patients who underwent radiation treatment and those who did not did not have any significant differences in the requirement for adjuvant medical therapy at the end of the study (38/66 versus 18/28, P=0.5).

The findings of the single-center study were presented at the American Association of Clinical Endocrinologists’ annual meeting.

“As many of you know, acromegaly is most commonly due to somatotroph adenoma, and is associated with increased morbidity, mortality, and decreased quality of life, if uncontrolled,” Donegan explained during an oral presentation. “If IGF-1 and growth hormone is normalized, then mortality can be similar to the general population.”

In order to address this, Donegan noted her research group aimed to assess the outcomes, as well as complications associated with radiation treatment, which is currently considered the third-line therapy for chronic acromegaly. Donegan said radiation treatment is not currently a very common form of treatment, particularly due to associated risk factors, such as cerebrovascular complications and hypopituitarism.

The study included individuals who were diagnosed with acromegaly and failed to achieve remission with surgical treatment. A total of 139 patients were included, who all underwent pituitary surgery, but continued to have abnormal IGF-I levels post-surgery.

Over half of participants underwent radiation treatment (65%, 90 of 139), with the majority exposed to Gamma Knife radiosurgery (86%). After a minimum of six-months following radiation treatment, patients experienced a mean time of 26 month to remission (6 to 223 months).

The groups did differ, Donegan said: the radiation treatment group had significantly larger tumors than those who did not undergo radiation (2 0.9 cm vs 1.4 0.6 cm, P0.001). Similarly, radiation-treated patients had a significantly higher incidence of cavernous sinus invasion (60% vs 22%, P=

There were no significant differences for risk of death between both participant groups (P=0.5), although Donegan said there were eight deaths reported throughout the duration of the trial. Other adverse events reported included one instance of stroke in the radiation group, although it was not thought to be due to the treatment.

However, Donegan suggested it is important to consider that “there is a possibility of developing anterior pituitary deficits, which needs to be borne in mind when thinking of the treatment algorithm for individual recurrent or persistent acromegaly.” She reported there was an elevated rate of development of new anterior pituitary hormonal deficit without a notable previous history of dysfunction before radiation (28 patients, 33%), most common being adrenal insufficiency.

When a member of the audience inquired about what methods were used to assess participants who developed ACTH deficiency during the study, Donegen responded they did not conduct formal insulin tolerance tests, and instead, analyzed samples of the participants cortisol.

2017-05-04T17:37:52-0400

View original post here:
Radiation Tx for Persistent Acromegaly Safe, Effective – MedPage Today

Hypopituitarism. Medical information about Hypopituitarism …

Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Prolactinoma written for patients

Hypopituitarism is the inability of the pituitary gland to provide sufficient hormones, due to an inability of the pituitary gland to produce hormones or due to an insufficient supply of hypothalamic-releasing hormones.

Symptoms depend on the degree of hormone depletion and the rapidity of onset. Hypopituitarism is usually a mixture of several hormonal deficiencies but rarely involves all the pituitary hormones. Hypopituitarism is usually chronic and lifelong, unless successful surgery or medical treatment of the underlying disorder can restore pituitary function.[1]

Taken from the results of one study:[1]

The most common cause of hypopituitarism is anterior pituitary tumours. The causes of hypopituitarism include:

See also the separate article on Pituitary Function Tests.

Hypopituitarism is sometimes associated with diabetes mellitus, dyslipidaemia, cardiovascular disease and osteoporosis.[1]

Patient Pro App Immediate reference All leaflets, without any ads Download

View post:
Hypopituitarism. Medical information about Hypopituitarism …

Shannen’s illnesslife-threatening or not? – Trinidad & Tobago Express

As a practising specialist in internal medicine with 34 years of professional experience at the San Fernando General Hospital, and as a past president of the Council of the Medical Board of Trinidad and Tobago (2004-2010), I am calling on the Medical Association of this country, through its president, to set the record straight with regard to the utterances of the Minister of Health, Terrence Deyalsingh, who continues to insist that the hereditary haemoglobinopathy called beta thalassaemia major, which is what has been reported in the media that the child Shannen Luke suffers from, is not a life-threatening illness in this country.

His statement is patently untrue. The minister has stated in the Parliament that he has obtained five independent professional opinions from doctors in this country and Barbados in support of his position. Further, he has insisted that he has formed his opinion based on the recommendation of the board that advises the Children’s Life Fund. I am also, therefore, calling on this board to publicly outline their position regarding the advice given to the minister as it pertains to this specific issue.

Having not been a party to the details of this child’s diagnosis, I am guided solely by media reports. All of the reports that I have read concerning the issue of this unfortunate child’s illness consistently attest to the fact that she has been diagnosed with beta thalassaemia major.

Beta thalassaemia major is a hereditary haemoglobinopathy that results in variable phenotypes depending on the extent of the patient’s inability to synthesise non-alpha globin chains. Based on media reports, including an excerpt of a referring letter from the child’s attending haematologist taken together with what the Minister of Health has said in the Parliament, one can reasonably conclude that this child suffers from beta (0) thalassaemia which refers to mutations of the beta-globin locus that result in the absence of production of beta globin. This is to be distinguished from beta thalassaemia intermedia and beta thalassaemia minor.

Only the last of these mutations can truly be considered to be non-life-threatening in the context of the present state of development of the health services in this country.

Beta (0) thalassaemia is a rare illness with a reported annual global incidence of just one in 100,000. Such children usually present with severe anaemia during the first two years of life. These children require repeated and regular transfusions of red cells which, in turn, if not managed properly with commensurate parenteral iron chelating therapy, e.g., deferoxamine (Desferal), administered through a continuous infusion pump device, will lead inevitably to a systemic iron overload with resultant organ failure.

Are infusion pumps routinely and reliably provided by Mr Deyalsingh’s ministry today?

Can he say that these patients reliably receive a supply of deferoxamine?

How often are they transfused and how safe are these red cell transfusions? Inadequacy in any one of these aspects of treatment poses a threat to life!

Furthermore, poorly transfused individuals with this disease suffer from obligatory resultant conditions that reduce their life expectancy considerably. On the other hand, regular transfusions in the absence of addressing iron overload similarly lead to a range of pathologic entities, e.g., diabetes, hypothyroidism, hypopituitarism, adrenal insufficiency and most frequently cardiomyopathy.

How on earth then, can the Minister of Health insist that this illness, such as it is reported to be, is not life-threatening?

See the article here:
Shannen’s illnesslife-threatening or not? – Trinidad & Tobago Express

Growth Hormone Deficiency Following Complicated Mild Traumatic Brain Injury – Lexology (registration)

Traumatic brain injury (TBI) is considered the main cause of hypopituitarism in adults and growth hormone (GH) deficiency is the most common pituitary deficit associated with TBI.

According to Cedars-Sinai, even after we stop growing, adults need growth hormone. Growth hormone plays a role in healthy muscle, how our bodies collect fat (especially around the stomach area), the ratio of high density to low density lipoproteins in cholesterol levels, and bone density. In addition, growth hormone is needed for normal brain function.

A recent study aimed to assess pituitary function and GH deficiency in adult patients at different time durations following complicated mild TBI, according to the Glasgow Coma Scale (GCS). The study also aimed to evaluate whether mild TBI patients with GH deficiency had developed alterations in the glycolipid profile.

Forty-eight patients (34 men and 14 women) with complicated mild TBI were included in the study. Twenty-three patients were evaluated at 1 year (Group A), and 25 patients at 5 years or longer after the injury (Group B). All patients underwent basal hormonal evaluation for pituitary function. GH deficiency was investigated by the combined test (GH releasing hormone + arginine). The glycolipid profile was also evaluated.

Researchers report that GH deficiency occurred in 8/23 patients (34.7 percent) of Group A and in 12/25 patients (48 percent) of Group B. In addition, two patients, one in each group, showed evidence of central hypothyroidism. Patients examined one-year or several years after complicated mild TBI had a similarly high occurrence of isolated GH deficiency, which was associated with visceral adiposity and metabolic alterations.

These findings suggest that patients with complicated mild TBI should be evaluated for GH deficiency even if several years have passed since the underlying trauma.

Link:
Growth Hormone Deficiency Following Complicated Mild Traumatic Brain Injury – Lexology (registration)

Hypopituitarism Symptoms, Causes & 8 Natural Remedies

The loss of pituitary gland hormone production also known as hypopituitarism can be a serious, life-long condition. The pituitary gland is our master gland. Ithelps to produce many hormones that are necessary for our bodies to function properly. Symptoms for this rare condition can be severe. However, with appropriate treatment, individuals with hypopituitarism should be able to live normal, productive lives. For some people, hormone replacement therapy may be necessary. There are also ways to balance your hormones naturallythat can beuseful as well.

Hypopituitarism refers to under-functioning of the pituitary gland. The pituitary gland is a tiny organ about the size of a pea. Its locatedat the base of the brain. Known as the master gland of the body, it produces many hormones that travel throughout the body. It directs certain processes andstimulates other glands to produce hormones.

A person with hypopituitarism has a pituitary gland that doesntproduce one or more of its hormones, or doesnt produce enough of them. This disorder can affect any number of the bodys routine functions, including growth, blood pressure and reproduction.

According to research published in Postgraduate Medical Journal, the prevalence of hypopituitarism is 45 cases per 100,000 people and the incidence rate is about 4 cases per 100,000 people, per year. Nearly 50 percent of patients have 3 to 5 pituitary hormone deficits. (1)

Hypopituitarism symptoms are sometimes not obviousand may be overlooked. The severity of symptoms typically depends on which pituitary hormones are lowand the extent of hormone deficiency. Some common signs and symptoms of hypopituitarism include:

Hypopituitarism symptoms depend on which hormone or hormones are missing. Symptoms associated with specific hormone deficiencies are listed below:

Adrenocorticotropic hormone (ACTH) deficiency.Fatigue, low sodium in blood, weight loss and skin paleness.

Thyroid-stimulating hormone (TSH) deficiency. Fatigue, weight gain, dry skin, constipation, sensitivity to cold

Luteinizing hormone (LH), Follicle-stimulating hormone (FSH) deficiency.Loss of periods for women, erectile dysfunction and impotence for men, loss of sex drive and infertility.

Growth hormone (GH) deficiency.Lack of growth (height) for children and adolescents, increased body fat, failure to achieve normal peak bone mass or decreased muscle and bone mass.

Prolactin (PRL) deficiency.Inability to breast feed

Oxytocin deficiency.Couldmake breastfeeding more difficult.

Antidiuretic hormone (vasopressin) deficiency.Frequent urination during the day and night, dilute urine and excessive thirst (3)

The progressive loss of pituitary hormone secretion is usually a slow process. Itcan occur over a period of months or years. However, occasionally hypopituitarism does start suddenly with a rapid onset of symptoms.

Generally, growth hormone is lost first. Then luteinizing hormone deficiency occurs. The loss of follicle-stimulating hormone, thyroid stimulating hormone, and adrenocorticotropin hormones and prolactin typically follow much later. (4)

Anumber of factors or health conditions can cause hypopituitarism. These include diseases of the pituitary gland or diseases of the hypothalamus that cause diminished secretion of hypothalamic releasing hormones. These hypothalamus diseases reduce the secretion of corresponding pituitary hormones.

Certain tumors can also affect pituitary gland function; this includes brain tumors, pituitary gland tumors and hypothalamus tumors. As a tumor gets bigger, it can compress and damage pituitary tissue, thereby interfering with hormone production. The most common cause of hypopituitarism is a pituitary tumor, also known as a pituitary adenoma. A pituitary tumor isalmost always benign. However,it puts pressure on the restof the pituitary gland. It also limits or even destroys the pituitary glandsability to produce hormones appropriately.

Your pituitary gland may also stop producing one or more of its hormones because of a traumatic injury. This can include brain surgery, a brain infection or a head injury.

Diseases caused by inflammation, impaired immune function or abnormal growth of tissue can causethe pituitary gland not to work properly. (5) This includes infections of the brain, such as meningitis, infections such as tuberculosis, syphilis and mycoses, and the following inflammatory diseases:

Other health issues that may lead to hypopituitarism include: a severe loss of blood during childbirth, which may cause damage to the front part of the pituitary gland (this is known Sheehans syndrome or postpartum pituitary necrosis), genetic mutations resulting in impaired pituitary hormone production, radiation damage and diseases of the hypothalamus.

Sheehans syndrome is a condition that affects women who lose a life-threatening amount of blood in childbirthand/or dont have enoughoxygen after childbirth. It is one of the most common causes of hypopituitarism in both underdeveloped and developing countries. (6)

Various studies have also looked into the effects of radiation damage and its link to hypopituitarism. Data shows that with low radiation doses, growth hormone deficiency usually occurs in isolation in about 30 percent of patients. With higher radiation doses (30 to 50 Gy), the incidence of growth hormone deficiency can reach 50 to 100 percent of patients. Researchers have also found that with higher dose cranial irradiation or following conventional irradiation for pituitary tumors, multiple hormonal deficiencies happenin 30 to 60 precent of patients after ten years of follow-up. (7)

Research shows that hypopituitarism is treatable. A patient with this condition should be able to perform normal activities as long as the appropriate hormonal therapy is used consistently and properly.

Hormone replacement therapyregulates circulating hormones, restores normal physiology as closely as possible and eliminates symptoms of hormone problems. To treat hypopituitarism, the replacement of deficient hormones is required for life. Thiscan be discouraging for patients who resist long-term therapy because of the fear of adverse effects. One rule of hormone replacement therapy is that no one dose will suit every patient. Because of this, when hormone replacement therapy is prescribed, the patient must be seen regularly to check see how they are responding to the treatment,and to change the dose if needed. (8)

Hormone replacement medications may include:

According to research published in Expert Opinion on Pharmacotherapy, lifelong therapeutic replacement of target hormonal deficiencies is necessary to avoid potentially life-threatening complications of hypopituitarism. But, there may be problems associated with administration and routine monitoring of this treatment. An ongoing challenge is to create and manage a helpfulplanof tailoring hormonal replacement regimens for individuals in order to avoid morbidity and mortality associated with hypopituitarism. (9)

Although the goal of hormone replacement therapy is to enable the patient to live a normal life, there are some risks involved in this type of therapy. Hormone replacement at doses that are higher than needed, especially in the case of cortisol, may harm the heart, bones and other organs. On the other hand, too low a dose of cortisol increases the risk of adrenal insufficiency, which is why patients must take additional cortisol when they are in stressful situations. (10)

Some medications, like human growth hormone replacement, may have side effects. These side effects include ankle swelling, joint aches and an increase in blood sugar levels.

People who havehypopituitarism a long time have a slight shorterlife span due to vascular causes, such as heart attacks and stroke, and infections. Although the reasons for this are not clear, patients with hypopituitarism should be screened for additional cardiovascular risk factors. They should also take steps to control their risk of developing cardiovascular issues. (11)

1. L-arginine

L-arginine is a type of amino acid that stimulates the production of certain hormones. These include especially beneficial growth hormones and insulin. L-arginine can help to reduce the symptoms of hypopituitarism, such as hair loss. It can also help to balance the bodys fluids, heal wounds, boost sperm production and allow for blood vessel relaxation.

A 2005 studypublished in Growth Hormone and IGF Research found that 5 to 9 grams of oral arginine caused a significant growth hormone response, which started approximately 30 minutes after ingestion and peaked approximately 60 minutes after ingestion. (12)

To naturally help your body make and use more L-arginine, eat clean sources of protein. These include cage-free eggs, cultured yogurt, grass-fed beef, pasture-raised poultry, liver and organ meats, wild-caught fish, walnuts and almonds.

2. Probiotics

The gut microflora has metabolic effects. This is why they are sometimes given to preterm infants. Research shows that young children who receive probiotic supplementation may achieve faster growth. (13) Research also suggests that probiotics cause significant elevations in growth hormone and testosterone levels in animals. (14)

Aside from taking a daily supplement, use probiotic foods to boost your intake of these healthy bacteria. This includes kefir, cultured vegetables, cultured yogurt, raw cheese, kombucha, apple side vinegar and miso. At the same time, its important that you steer clear of foods that can cause damage to your gut. These includeprocessed foods, hydrogenated oils and added sugar.

3. Copper

A severe copper deficiency may harm the body in multiple ways, including slowing growth. Research shows that adequate intake of copper and other micronutrients isneeded for childhood growth promotion. Copper plays an important role in bodily growth and repair. (15) The body uses copper frequently and it cannot store the mineral in sufficient amounts. Eating copper-rich foods like nuts, seeds, wild seafood, beans, liver and oysters can help you to prevent a copper deficiency and maintain hormone balance.

4. Glycine

Glycine is an amino acid that plays a role in the production of human growth hormone. Studies show that glycine increases growth hormone levels. Evidence is mixedabout its effectivenessfor people with an existing growth hormone deficiency. A 2003 study published in Nutritional Neuroscienceinvolved 42 healthy participants who received either five grams of a nutritional supplement containing glycine, glutamine and niacin, or placebo, twice daily for three weeks. The nutritional supplement containing glycine increased serum growth hormone levels by 70 percent relative to placebo. (16)

5. Adaptogen Herbs

Adaptogen herbs help to balance, restore and protect the body. They respond to any influence or stressor, normalizing your physiological functions. Research shows that adaptogen herbs have positive benefits on the reproductive health of both men and women. They can improve fertility and sexual desire. Adaptogens may also have beneficial effects on the cardiovascular system, helping to protect the heart and regulate blood pressure. This is important because people with hypopituitarism are at a greater risk of deathdue to cardiovascular issues. (17)

Some of the most powerful adaptogen herbs include ginseng, holy basil, rhodiola, ashwagandha and astragalus root. Because these herbs affectstress hormones, you should only use them under the care of your healthcare provider. This is especially important if you are already onhormone replacement therapy.

6. Healthy Fats

Eating healthy fats, such as coconut oil, avocados, grass-fed butter and wild-caught salmon, help to balance your hormones naturally. The body needs short, medium and long-chain fatty acids to create hormones. These essential fats are not only fundamental building blocks for hormone production. They also reduce inflammation and improve heart health. (18)

7. Exercise

One of the many benefits of exercise is its ability to increase growth hormone prevalence. Research conducted at Syracuse University suggests that exercise is a very potent stimulator of growth hormone release. There is considerable research documenting the dramatic rise of growth hormone. Studies suggest that exercise can increase growth hormone levels by 300 to 500 percent. (19)

8. Sleep

Adequate sleep, which means 7 to 8 hours every night, is essential for hormone balance. Your hormones work on a schedule. The body regulatescortisol levelsin the middle of the night. This helpsto give your bodya break from your flight or fight stress response. Sleep helps to keep stress hormones balanced. It also helps to build energy and allow the body to recover from stress properly. (20)

Hypopituitarism can be a life-threatening condition if its not regulated properly. Natural remedies should always be used under the care of your doctor. For some people, hormone replacement therapy may be a neededtreatment.

Leaky gut syndrome is a rapidly growing condition that millions of people are struggling with and dont even know it. From the sound of it, you might think leaky gut syndrome only affects the digestive system, but in reality it can lead to many other health conditions. Because Leaky Gut is so common, and such an enigma, Im offering a free webinar on all things leaky gut. Click here to learn more about the webinar.

. Bookmark the

.

See more here:
Hypopituitarism Symptoms, Causes & 8 Natural Remedies

Penn Medicine Researchers Receive Distinguished Investigator Awards – Newswise (press release)

Newswise Scott Halpern, MD, PhD, MBE, an associate professor of Medicine, Epidemiology, and Medical Ethics and Health Policy, and director of the Palliative and Advanced Illness Research (PAIR) Center, and Peter J. Snyder, MD, a professor of Medicine in the division of Endocrinology, Diabetes and Metabolism, will be presented with the 2017 Association for Clinical and Translational Science (ACTS) Distinguished Investigator Award for Career Achievement and Contribution to Clinical and Translational Science at Translational Science 2017, the organizations annual meeting, in Washington, D.C. Halpern will also receive the American Federation for Medical Researchs (AFMR) Outstanding Investigator Award at the meeting next month.

The ACTS Distinguished Investigator Award recognizes senior investigators whose innovative research or education leadership has significantly impacted clinical and translational science. The AFMR Outstanding Investigator Award is presented annually to an investigator age 45 or younger in recognition of excellence in biomedical research.

The ACTS Distinguished Investigator Award for Translation from Clinical Use into Public Benefit and Policy & AFMR Outstanding Investigator Award

Dr. Halpern is also the founding director of the Fostering Improvement in End-of-Life Decision Science (FIELDS) program, and deputy director of the Center for Health Incentives and Behavioral Economic (CHIBE). By blending ethical analyses and empirical research, Dr. Halpern’s work promotes the ideals of fairness and value in how scarce healthcare resources, including transplantable organs, ICU beds and services, and clinicians time are allocated to seriously ill patients. The PAIR Center conducts large, pragmatic randomized trials of interventions that seek to improve the lives of all people affected by serious illness. The FIELDS program includes scholars from multiple health-related disciplines who use principles of behavioral economics in an effort to understand and improve upon the healthcare decisions made by seriously ill patients and their family members and clinicians. Finally, his work through the CHIBE develops behavioral economic interventions that motivate smoking cessation, research participation, and reductions in the use of low-value healthcare services, without unduly constraining autonomous choice.

Dr. Halperns research is supported by the National Institutes of Health (NIH) and by a number of foundations. He is an elected member of the American Society of Clinical Investigation, and a member of the editorial boards of the Annals of Internal Medicine and the American Journal of Bioethics. From 2013 2015 he was an anniversary fellow at the Institute of Medicine. He holds a bachelors degree from Duke University, and an MD, PhD, MSCE and MBE from the University of Pennsylvania.

The ACTS Distinguished Investigator Award for Translation from Early Clinical Use to Applicability for Widespread Clinical Practice

Snyders clinical expertise is focused on neuroendocrinology, or the diagnosis and treatment of pituitary adenomas and other pituitary and hypothalamic abnormalities, including excessive and deficient pituitary hormone secretion. These conditions include acromegaly, Cushings disease, hyperprolactinemia, gonadotroph and other clinically nonfunctioning adenomas, other pituitary and hypothalamic tumors, hypopituitarism, and diabetes insipidus. In clinical practice, he also specializes in male reproductive endocrinology, the diagnosis and treatment of hypogonadism and infertility in men.

Over his nearly five-decade career, Snyder has examined the effects of hormones on bone and pituitary adenomas. Most notably, Snyder was the principle investigator of The Testosterone Trials, a multicenter study of seven coordinated trials of the effects of testosterone in elderly men with low testosterone on physical function, vitality, sexual function, cognitive function, anemia, bone and cardiovascular risk.

Snyder is also involved in several professional societies including the American Society for Bone and Mineral Research, the American Society for Clinical Investigation, the Association of American Physicians, and the Endocrine Society. He holds a bachelors degree from Williams College and a medical degree from Harvard University.

### Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.

Newswise The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community. Contacts

Original post:
Penn Medicine Researchers Receive Distinguished Investigator Awards – Newswise (press release)

Fighting Cancer With Fundraising: Meet Milwaukee’s Dr. John Hanson – Milwaukee Magazine

Dr. John Hanson has a colorful, stylish office in the Cudahy Tower, converted from an old apartment, reducing his morning commute to a short stroll from a condominium in the building. A retired oncologist, Hanson now spends his time spearheading his 5-year-old John P. Hanson Foundation for Cancer and Cellular Research, which supports research into cell therapy and other forms of cancer immunotherapy, advanced treatments that direct the power of the bodys immune system (including T-cells) against unwanted cancer cells. Hanson is currently gathering funding to support up to three young researchers at the cutting-edge Robert H. Lurie Comprehensive Cancer Center at Northwestern University, with hopes of one day endowing a professorship.

Should cancer patients challenge their doctors?I think thats fine. Theres no cure. There might be two or three different options. And the next thing is, is there a clinical trial or an attempt to improve on standard practices available? Its all about the patient getting better.

Must the immune system miss something for a tumor to form? No. Its not missing something. What happens is the cancer outfoxes everyone. Instead of supporting the body, it begins to support itself and becomes self-aggrandizing.

Cell therapy sounds great. Does it have limitations?It works extremely well with melanoma because there are large genetic differences. Breast cancer has been treated successfully. A few colon cases have been treated successfully. A pancreatic cancer has been treated successfully, one or two [times]. The imperative is you must develop this [approach] for common cancers because theyre what kill people. It works extremely well with melanoma because there are large genetic differences. Breast cancer has been treated successfully. A few colon cases have been treated successfully. A pancreatic cancer has been treated successfully, one or two [times]. The imperative is you must develop this [approach] for common cancers because theyre what kill people.

During immunotherapy, can the immune system target things other than cancer? That does happen. Diabetes can occur. Hypothyroidism can occur. Hypopituitarism can occur, and bowel diseases can happen. Its a reaction to the immune system being turned on too much.

What was it like to work with cancer patients? Did you find it rewarding? Oh sure. You can help the sick. The art is to listen to what the patient wants. If you listened enough early on, you could say, This is what you want, and this is what I can do. If they wanted to do something high risk, we would talk about it for a week or two to make sure they got it and understood what the risks were. The goal was, I am going to get you through this. You can do this, and you will do this. We have to get to the end of a course [of treatment] to see if it works. Theres a sorrow at death, but we tried as best we could. Can we learn something to help the other families, the other patients? Almost always we do. Was it worth it? Absolutely. Every human being who has cancer wants to live.

Why hasnt immunotherapy taken over the field?Doctors are committed to the life and well-being of patients, and theyre not convinced it works. But youre dealing with people who are dying and sick. I think theres an imperative. You cant keep putting up with the same old shit. Its not in human nature to accept that what is [is beyond improvement]. You have to try.

comments

See the original post here:
Fighting Cancer With Fundraising: Meet Milwaukee’s Dr. John Hanson – Milwaukee Magazine

Thymomas Trigger Newly Described Autoimmune Endocrine Disease – Oncology Nurse Advisor


Oncology Nurse Advisor
Thymomas Trigger Newly Described Autoimmune Endocrine Disease
Oncology Nurse Advisor
Thymomas, a rare type of cancer in the thymus gland, can result in a newly described autoimmune disease, potentially leading to hypopituitarism, according to a recent study in Scientific Reports. Understanding the underlying mechanisms could improve …

More:
Thymomas Trigger Newly Described Autoimmune Endocrine Disease – Oncology Nurse Advisor

Cold Springs FCCLA brings home state awards – Cullman Times Online

Cold Springs FCCLA students took home an array of honors at state conference, with one student advancing to compete nationally.

On March 9-10, 2017, Cold Springs FCCLA students attended the FCCLA State Meeting in Montgomery. Members throughout Alabama gathered to increase their leadership skills, explore career options, compete in the state FCCLA STAR Events and elect a new team of state officers. With FCCLA there are unlimited opportunities for our youth.

This year Cold Springs had a student, Matthew Blair, to run for the FCCLA Executive Council Officer position. Matthew ran for this office with 10 other young adults from all over Alabama. Only six are chosen for the Executive Council. Matthew gave his speech and answered an on stage question to over 800 members, advisors, and guests. Matthew was voted in by his peers. He will be required to represent the state of Alabama at state and national meetings.

Cold Springs FCCLA had five students to complete the Power of One projects and be recognized at the state meeting: Rachel Haynes, Jessica Roden, Andrew Blair, Matthew Blair, and Stormy Schmidt received a certificate of completion.

Power of One helps students find and use their personal power. Each youth created a Power of One project that relates to one of the following five units:

A better you: Improve personal traits.

Family ties: Get along better with family members.

Working on working: Explore work options, prepare for a career, or sharpen skills useful in business.

Take the lead: Develop leadership qualities.

Speak out for FCCLA: Tell others about positive experiences in FCCLA.

Cold Springs students also competed in the FCCLA STAR Events Competition. These are competitive events in which members are recognized for proficiency and achievement in chapter and individual projects, leadership skills, and career preparation.

Rachel Haynes competed in the Career Investigation category and won gold. Her project title was Labor Lawyer. She will be representing the state of Alabama in this category at Nationals this summer in Nashville.

Matthew Blair, Raegan Lindsey, and Stormy Schmidt won gold in the Illustrated Talk category. They presented about teen depression and suicide.

Jessica Roden placed silver in the Life Event Planning category. Her topic was, Dedication to a Preacher. She planned, organized, and presented her project.

Kylie Gann and Samantha Willcutt won bronze in the Focus on Children category. They discussed and presented the topic of Living with Hypopituitarism. The girls wanted other students to understand what it is like to live with this. One of the girls cousins was born with this.

FCCLA has provided unlimited possibilities for our young adults at Cold Springs and other area schools. Its helps prepare todays teens for tomorrows workforce. It provides personal growth, leadership development, and career preparation opportunities for students in Family and Consumer Sciences. Advisor is Stephanie Blair.

More:
Cold Springs FCCLA brings home state awards – Cullman Times Online

Hypopituatarism – a lesser-known effect of traumatic brain injury – Lexology (registration)

Our understanding as to how the brain works has developed over the years with medical research. It is an extremely complex organ and when trauma happens it can be very unpredictable as to how the injured person will be affected and what treatment they will require. The problems that can occur are generally split into three areas:

Another area which can be affected following a brain injury which is less commonly understood is hormonal. The pituitary gland is found at the base of the brain. It is approximately the size of a pea and is attached to the brain by a thin stalk. This gland is often referred to as the master gland and is very important in that as well as producing hormones it regulates and controls the other glands in the body which produce hormones.

The pituitary gland is vulnerable to damage if someone suffers trauma to their brain given its location at the base of the brain. Damage to the pituitary gland can result in the gland failing to produce sufficient amount of hormones and this is known as hypopituitarism.

Symptoms of hypopituitarism

It is often not immediately apparent that someone has suffered damage to the pituitary gland and developed hypopituitarism. This is because the symptoms may not develop for a number of weeks, months or even years.

When the symptoms become apparent it is often the case that these can overlap with those suffered as a result of the actual brain injury and be overlooked and therefore misdiagnosed. The symptoms are often subtle and difficult to distinguish meaning treatment can therefore be delayed.

The most common symptoms of hypopituitarism are:

If you display some of these symptoms and your doctor suspects you may be suffering from hypopituitarism they can carry out blood tests to identify any abnormalities. A CT scan may also be carried out to rule out the possibility of a growth or tumour on the pituitary gland. You may then be referred to an endocrinologist a specialist doctor who diagnoses and treats hormone imbalances. Dependant on the particular imbalance you are suffering from, the treatment should aim to return the balance to your hormone levels.

You may be prescribed hormone replacement medication. The endocrinologist will then have to monitor your hormone levels regularly to ensure the levels are kept at a normal level and hopefully ensuring normal hormonal function can resume. Medication may require adjustment to ensure the correct dosage is found and the prescribed treatment acts in conjunction with any other medication which the person may be prescribed to deal with the other symptoms of their brain injury. Hormone replacement treatment will likely be life-long if the damage to the pituitary gland is significant.

Our understanding as to the frequency at which hypopituatarism develops following traumatic brain injury is still in its early stages. We do not yet have accurate statistics to illustrate the likelihood of developing hypopituitarism following brain injury however it is beginning to become clear that it may be more common than previously thought. It is important that patients are warned prior to discharge from hospital following a brain injury to be vigilant as to the symptoms of hypopituitarism. The danger of misdiagnosis or delayed diagnosis could lead to serious consequences however, if identified, hormone replacement treatment is often very successful.

If you have any concerns that you are experiencing symptoms of hypopituitarism following a brain injury it is important that you speak to your GP or other treating doctors. The blood test is quick and easy to undertake to diagnose the condition.

If you have been diagnosed with this condition as a result of an accident, and have suffered a traumatic brain injury, then this condition ought to be taken into account when bringing your personal injury claim. If your medical team have delayed in diagnosing or misdiagnosed your hypopituitarism then you may have a claim for medical negligence.

Read the original here:
Hypopituatarism – a lesser-known effect of traumatic brain injury – Lexology (registration)

Joanna Lane:: Brain injury can cause treatable pituitary disorder – Madison.com

Dear Editor: I am writing this after reading Karl Curtis’ column on brain injuries in the hope that it may be helpful to some of your readers.

Our son Chris committed suicide eight years ago at the age of 31. He’d had a head injury long ago, in childhood, which he’d seemed to recover from fine. But we discovered after his death that he’d never been able to have full sex with his girlfriend, and also that his depression had been far worse than we knew, going back 10 years at least.

We looked it up and found that head injury, even mild (which Chris’ wasn’t; he fractured his skull) can cause damage to the pituitary gland, and the effects can be depression, lost sex drive, lost fertility, obesity and chronic fatigue, plus less serious symptoms like intolerance of heat or cold. The pituitary disorder (post-traumatic hypopituitarism or PTHP) may show immediately, or not until many years later. It is treatable by replacing the hormones which the pituitary can no long make.

Cranial irradiation can cause hypopituitarism also.

Growth hormone replacement can restore clear thought and energy levels, and may reduce weight. It can also help fatigue and depression. The other pituitary hormones that may need replacing are ACTH, LH/FSH, and TSH. LH/FSH replacement can restore sex drive and fertility.

For more detail plus the research see my book “Mother of a Suicide” available from Amazon.

Joanna Lane

London, UK

Send your letter to the editor to tctvoice@madison.com. Include your full name, hometown and phone number. Your name and town will be published. The phone number is for verification purposes only. Please keep your letter to 250 words or less.

Read the rest here:
Joanna Lane:: Brain injury can cause treatable pituitary disorder – Madison.com

Hypopituitarism – familydoctor.org

How is hypopituitarism treated?

Your doctor will treat the condition that is the cause of your hypopituitarism first. This can help restore your pituitary glands ability to produce hormones.

If a tumor on your pituitary gland is causing your hypopituitarim, your doctor may recommend surgery to remove it or radiation therapy to shrink it.

If your body does not produce enough of one or more pituitary hormones after treating the underlying condition, your doctor may prescribe a hormone replacement medicine to add to your bodys hormone production.

Hormone replacement medicines include:

If you are taking hormone replacement medicine, your doctor may want to monitor the levels of hormones in your blood to make sure youre getting the right amount of replacement hormones.

If you become very sick (such as with the flu) or go through a stressful time, your doctor may adjust the dose of replacement hormone you take to act the way a normally functioning pituitary gland would act in response to these situations. You might also need a dose adjustment if you become pregnant or have a significant change in weight.

You should carry a medical alert card and bracelet at all times so that emergency medical workers know what kind of care you need in case of emergency.

See original here:
Hypopituitarism – familydoctor.org

New autoimmune disease triggered by thymomas – Science Daily


Science Daily
New autoimmune disease triggered by thymomas
Science Daily
A Japanese research group has discovered that a newly-identified autoimmune endocrine disease that leads to hypopituitarism is caused by thymomas (a type of tumor originating from the thymic gland). These underlying mechanisms could help to …

Go here to see the original:
New autoimmune disease triggered by thymomas – Science Daily

Hopsital apologises to mother for parking fines caused by faulty system – View News

YEOVIL Hospital has apologised to the mother of disabled girl who keeps getting fined by a faulty car parking system as she takes her daughter for treatment.

Nicky Fordon regularly drives daughter Rebecca to the hospital as she has learning disabilities and suffers from the rare condition diabetes insipidus and hypopituitarism.

Nicky visits Yeovil Hospital more than once a week to make sure Rebeccas sodium levels are sufficient because she cant retain liquids.

Nicky, 52, has a blue badge and her car registration is registered with the hospital yet she has racked up fines of 400 in the last two months.

On each occasion she has protested and the ticket has been cancelled but only after she has had to make yet another journey to the hospital to deal with it in person. The hospitals cameras monitoring the car parking entrance keep registering her as parking there and not in a disabled parking bay.

Mum-of-three Nicky said: Its stressful, time-consuming and completely unnecessary.

When I had the first one I was really worried I couldnt work out what Id done. It showed my car and registration and it said Id stopped there for an hour and a half but it could only have been for a few seconds while I waited for a parking bay to be free or to let someone out. I was in the car and the brake lights were on.

I feel like I spend my life at the hospital so its a real pain to have to go back with the tickets. Theres no number you can phone to talk to anyone, Ive got to go in person.

I think there must be loads of elderly people who just pay without questioning it.

A Yeovil Hospital spokeswoman said: We would like to apologise for the inconvenience caused to this lady who has received these fines in error.

The spaces out of the front of the hospital are controlled by ParkingEye, which uses number-plate recognition cameras.

We have assisted with dealing with each ticket on an individual basis but this issue will now be escalated to Parking Eye for them to investigate.

This is an unusual case and we would encourage this lady to get back into contact with us so we can address her concerns.

More here:
Hopsital apologises to mother for parking fines caused by faulty system – View News

Archives